Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.
Leonardo Gomes da FonsecaGuilherme Nader MartaMaria Ignez Freitas Melro BraghiroliAline Lopes ChagasFlair Jose CarrilhoPaulo Marcelo HoffJorge SabbagaPublished in: BMC cancer (2018)
In accordance with previous studies, CCT had a notable rate of adverse events. The poor prognosis of this cohort suggests that CCT may not alter the natural history of HCC after sorafenib progression.